ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 79 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $111,733 | -44.3% | 21,042 | 0.0% | 0.00% | – |
| Q2 2023 | $200,530 | +11.2% | 21,042 | +28.4% | 0.00% | – |
| Q1 2023 | $180,312 | -28.6% | 16,392 | -4.0% | 0.00% | – |
| Q4 2022 | $252,606 | -7.1% | 17,068 | +19.9% | 0.00% | – |
| Q3 2022 | $271,954 | -9.8% | 14,231 | +0.6% | 0.00% | – |
| Q2 2022 | $301,579 | +28.1% | 14,152 | +15.8% | 0.00% | – |
| Q1 2022 | $235,376 | -26.0% | 12,221 | -20.8% | 0.00% | – |
| Q4 2021 | $318,000 | -10.7% | 15,428 | +3.5% | 0.00% | – |
| Q3 2021 | $356,000 | -19.1% | 14,911 | -7.5% | 0.00% | – |
| Q2 2021 | $440,000 | +17.3% | 16,119 | +24.2% | 0.00% | – |
| Q1 2021 | $375,000 | +10.3% | 12,975 | +7.3% | 0.00% | – |
| Q4 2020 | $340,000 | +18.9% | 12,087 | +23.6% | 0.00% | – |
| Q3 2020 | $286,000 | – | 9,776 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 8,684,232 | $46,113,272 | 3.06% |
| Pivotal bioVenture Partners Investment Advisor LLC | 1,105,309 | $5,869,191 | 2.34% |
| Bain Capital Life Sciences Investors, LLC | 3,000,000 | $15,930,000 | 1.78% |
| Sio Capital Management, LLC | 635,969 | $3,376,995 | 1.04% |
| Rubric Capital Management LP | 5,034,530 | $26,733,354 | 1.00% |
| Tejara Capital Ltd | 309,179 | $1,641,740 | 0.93% |
| AlphaCentric Advisors LLC | 165,000 | $876,150 | 0.50% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,135,227 | $6,028,055 | 0.33% |
| Orbimed Advisors | 1,914,479 | $10,165,883 | 0.22% |
| Two Seas Capital LP | 164,807 | $875,125 | 0.18% |